374 related articles for article (PubMed ID: 17954367)
21. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
22. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
24. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
[TBL] [Abstract][Full Text] [Related]
25. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
26. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
27. [Effects of angiotensin II type 1 receptor blocker on triglyceride metabolism in the liver: experiment with Zucker fatty rats].
Ran JM; Lao GC; Xu G; Xie B; Zhang Y; Liu W; Feng Q; Guo J
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1557-61. PubMed ID: 18956640
[TBL] [Abstract][Full Text] [Related]
28. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
Courtney AE; McNamee PT; Nelson WE; Maxwell AP
Nephrol Dial Transplant; 2006 Dec; 21(12):3550-4. PubMed ID: 16968729
[TBL] [Abstract][Full Text] [Related]
29. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.
Seko Y
Clin Sci (Lond); 2006 Mar; 110(3):379-86. PubMed ID: 16336207
[TBL] [Abstract][Full Text] [Related]
30. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.
Sasaki H; Kamijo-Ikemori A; Sugaya T; Yamashita K; Yokoyama T; Koike J; Sato T; Yasuda T; Kimura K
Nephron Clin Pract; 2009; 112(3):c148-56. PubMed ID: 19390215
[TBL] [Abstract][Full Text] [Related]
31. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
[TBL] [Abstract][Full Text] [Related]
33. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
34. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K
Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Ogawa S; Mori T; Nako K; Ito S
Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
[TBL] [Abstract][Full Text] [Related]
36. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
37. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Inoue T; Node K
Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
[TBL] [Abstract][Full Text] [Related]
38. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
[TBL] [Abstract][Full Text] [Related]
39. Reply to Yang et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Mandal A
Clin Nephrol; 2006 Mar; 65(3):227; author reply 227-8. PubMed ID: 16550756
[No Abstract] [Full Text] [Related]
40. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H
Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
